Large Number of Drugs in Advanced Phase Clinical Trials

2026-08-05 03:01:48 Industry

1140

The Phase III products offer a huge potential in the future and their successful clinical trials can revolutionize their usage and clinical applications. The most promising pipeline is that of the monoclonal antibodies, owing to the low immunogenicity of this therapeutic product. Insulin products from companies such as, Novo Nordisk and Sanofi, in the late phase developmental stage are also of great potential and are aimed to efficiently regulate the blood glucose levels. Blood clotting factor products are also robustly present in the pipeline. Primarily aimed at hemophilia, these products can be expected to be of great therapeutic use for this blood disorder.

Research Analysis & Highlights

Increasing healthcare expenditure and constant investment by major pharmaceutical players will continue to bolster the Protein Therapeutics market which may reach the mark of US$ 208 Billion by 2020. According to our new research report, ?Global Protein Therapeutics Market Outlook 2020?, the growth within the market can also be attributed to increasing healthcare awareness and prevalence of diseases, and growth in the emerging markets.

The report takes into account all the key aspects of the worldwide protein therapeutics market and projects the market during the period 2015-2020. It prudently analyzes all the industry segments in an effective manner by focusing on market dynamics, that would drive, challenge and provide opportunities in the market, major players and products, recent developments, application support in terms of indications, geographical performance and last but not the least, current and future market size. Moreover, the report provides a brief summary of the recent trends that may have an impact on the future industry performance. The report also analyzes the industry lucrativeness through Porters Five Forces analysis. Overall, the report will prove to be a complete source of knowledge and analysis for clients and potential investors.

Some of the key highlights of the report are:

- mAbs continue to dominate the market, with a strong pipeline for the future
- Increasing government initiatives, to boost the healthcare sector
- Major drug manufacturers investing in protein therapeutics market
- Insulin segment expected to witness the highest growth, owing to the ever increasing diabetic population

For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM781.htm

Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm

ABOUT RNCOS

RNCOS is a leading industry research and consultancy firm incorporated in 2002. As a pioneer in syndicate market research, our vision is to be a global leader in the industry research space by providing research reports and actionable insights to companies across a range of industries such as Healthcare, IT and Telecom and Retail etc. We offer comprehensive industry research studies, bespoke research and consultancy services to Fortune 1000, Trade associations, and Government agencies worldwide.